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oAbstract
Background: Survivors of critical illness are at increased risk of fractures. This may be due
to increased osteoclast formation during critical illness, leading to trabecular bone loss.
Such bone loss has also been observed in Paget’s disease, and has been related to
deficient autophagy. Deficient autophagy has also been documented in vital organs and
skeletal muscle of critically ill patients. The objective of this study was to investigate
whether deficient autophagy can be linked to critical illness-induced bone loss.
Methods: Osteoclasts grown in vitro and their precursor cells isolated from peripheral
blood of critically ill patients and from matched healthy volunteers were analysed for the
expression of autophagy genes (SQSTM1, Atg3 and Atg7), and proteins (p62, Atg–5, and
microtubule-associated protein light chain 3–II (LC3–II)) and for autophagy and epigenetic
signalling factors via PCR arrays and were treated with the autophagy inducer rapamycin.
The effect of rapamycin was also investigated at the tissue level in an in vivo rabbit model
of critical illness.
Results: Many more osteoclasts formed in vitro from the blood precursor cells isolated
from critically ill patients, which accumulated p62, and displayed reduced expression of
Atg5, Atg7, and LC3–II compared to healthy controls, suggesting deficient autophagy,
whilst addition of rapamycin reduced osteoclast formation. PCR arrays revealed a
down-regulation of histone methyltransferases coupled with an up-regulation of negative
regulators of autophagy. Critically ill rabbits displayed a reduction in trabecular and
cortical bone, which was rescued with rapamycin.
Conclusions: Deficient autophagy in osteoclasts and their blood precursor cells at least
partially explained aberrant osteoclast formation during critical illness and was linked to
global histone hypomethylation. Treatment with the autophagy activator Rapamycin
reduced patient osteoclast formation in vitro and reduced the amount of bone loss in
critically ill rabbits in vivo. These findings may help to develop novel therapeutic targets
to prevent critical illness-induced bone loss.
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We have previously reported that circulating biomarkers of bone resorption were sub-
stantially elevated during critical illness whereas markers of bone formation were low [1].
Such an imbalance may predispose critically ill patients to impaired fracture healing,
osteoporosis, and increased risk of new fractures during intensive care unit (ICU) stay or2015 Owen et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
reativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
riginal work is properly credited.
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display an increased risk of fragility fractures up to 8 years after their stay in the ICU [2].
Interestingly, in an in-house rabbit model of prolonged critical illness trabecular bone
mineral density (BMD) and bone mineral content (BMC) were significantly reduced [3].
In addition, analysing osteoclast formation in vitro grown from peripheral blood
mononuclear cells (PBMCs) isolated from critically ill patients revealed an increase in
circulating early osteoclast precursors and the formation of much more mature, resorptive
osteoclasts from critically ill patient PBMCs [4]. However, the mechanisms behind this
increase in osteoclast formation remain unclear.
The importance of autophagic signaling for osteoclastogenesis was first realized when it
was discovered that mutations in the ubiquitin binding protein p62/SQSTM1 was
implicated in Paget’s Disease of Bone (PDB), a disease associated with rapid bone
remodeling and weakness due to aberrant osteoclastogenesis [5]. More recently, it has been
shown that autophagy regulates the lysosomal release of lysosomal components by
osteoclasts [6], and pharmacological inducers of autophagy reduce pathological osteoclast
formation [7]. We have also recently shown that autophagy is deficient in vital organs and
tissues from critically ill rabbits and humans, with an accumulation of p62 and a decrease in
the LC3II/I ratio contributing to mitochondrial dysfunction, organ failure, and adverse
outcome [8–10]. It is therefore possible that deficient autophagy may also contribute to the
increased osteoclast formation and activity during critical illness.
It has recently become apparent that alterations in gene expression alone are insufficient
to explain the dynamic and complex process of pathogenic osteoclast formation during
metabolic bone disease, and epigenetic regulation is likely to play a role. In particular, the
expression of key developmental genes are tightly regulated by methylation of histone H3
lysine 4 (H3K4me3) and lysine 27 (H3K27me3). Interestingly demethylation of H3K27me3
in osteoclast precursors has been associated with the expression of NFATc1, a marker of
mature osteoclast formation [11].
Epigenetic factors have also been implicated in regulating autophagy in various
pathological conditions [12]. Both epigenetic and autophagic regulation of signalling
pathways are known to be highly regulated by environmental factors, particularly during
skeletal remodelling [13]. Autophagy activators have shown promising effects against age-
related disorders in experimental models [14, 15]. In the clinical setting, the therapeutic
value of epigenetic modulators has recently been discovered for conditions such as
pre-malignancy and neurodegenerative disorders [16, 15].
We here hypothesize that deficient autophagy, in part related to global histone hypo-
methylation, may be involved in the increased osteoclast formation and activity during critical
illness. We also hypothesize that autophagy inducers could reverse this osteoclast phenotype
in vitro as well as the resulting bone loss in vivo in a rabbit model of critical illness.Methods
1. In vitro model of bone resorption during critical illness
Experimental subjects
Human peripheral blood was collected from prolonged critically ill patients (n = 6,
24–82 years of age, mean age 51 ± 20.1 years of age) and healthy control volunteers,
matched for age, sex, and body mass index (BMI) (n = 6, 25–90 years of age, mean
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in the ICU for 7 days or longer were selected by excluding those who had received
steroidal drugs or bisphosphonates in the past 12 months.
All protocols were approved by the Institutional Review Board of the Leuven University
(ML6195). Written informed consent was obtained from all healthy volunteers and from
the patients or, when the patient was unable to give consent, from the closest family
member.Peripheral blood mononuclear cell isolation and culture
Peripheral blood mononuclear cells were isolated using the Ficoll Hypaque density cen-
trifugation technique. For osteoclast differentiation, cells were seeded at a density of
5×105 cells per well [4, 17]. All cultures were performed in quadruplicate in 16–well
culture slides (VWR, Leuven, Belgium), and cells were cultured in α–MEM supple-
mented with 10 % foetal bovine serum (FBS), 100 IU/ml penicillin and 100 μg/ml
streptomycin. All cultures were maintained at 37 °C in a humidified atmosphere with
5 % CO2. For the induction of autophagy, cells were cultured in the presence of 1 nM
rapamycin (Cayman Chemical, Ann Arbor, MI, USA). After 14 days, PBMCs were fixed,
and stained for the osteoclast-specific marker tartrate-resistant acid phosphate (TRAP),
and the formation of TRAP positive multi-nucleated (more than three nuclei) cells was
quantified by counting the multi-nuclear stained cells in each well [18].Gene expression and protein analysis of osteoclast and autophagy markers
For gene expression analysis, PBMCs were seeded at 100,000 cells/cm2 and cultured for
14 days in α–MEM supplemented with 10 % FBS, 100 IU/ml penicillin and 100 μg/ml
streptomycin. Total RNA was isolated using the RNeasy kit (Qiagen Benelux, Venlo,
Netherlands), and cDNA was synthesized with the SuperScript III First Strand synthesis
system for real-time PCR (Invitrogen). Quantitative Real-Time SYBR Green (Invitrogen)
PCR was performed for osteoclast markers TRAF6, CD16 and NFATc1, and autophagy
markers SQSTM1, Atg3, and Atg7 according to the manufacturer’s protocol, with mRNA
levels normalized to β-actin expression. SYBR Green qPCR primers were designed to span
an intron so that only RNA-specific amplification was possible (See Table 2 for primer
sequences). Total RNA samples subjected to cDNA synthesis reactions in the absenceTable 1 Characteristics of critically ill patients and age-, sex, and BMI-matched healthy volunteer
controls whose peripheral blood was used to isolate PBMCs for in vitro osteoclast differentiation
studies
Characteristic Patients Controls p
n 6 6
Age (years), median (IQR) 51 (24–82) 53 (25–90) 0.88
Male gender, % 83 % 83 % >0.99
BMI (kg/m2), mean ± SD 25.6 ± 5.4 25.4 ± 2.9 0.93
ICU stay upon day of sampling (days), median (IQR) 15.3 (7–39) n/a
APACHE-II score upon day of sampling, median (IQR) 27.8 (12–41) n/a
WBC upon day of sampling, median (IQR) 14.2 (9–18) n/a
CRP upon day of sampling, median (IQR) 143.8 (31–303) n/a
Table 2 Primer sequences for qPCR analysis
Gene name Forward (5’-3’) Reverse (3’-5’)
Human
TRAF6 GCAAGTATGAATGCCCCATC TGGACATTTGTGACCTGCAT
CD16B CATTCCAAAAGCCACACTCA CCCAGGTGGAGAGAATGATG
NFATc1 GCATCACAGGGAAGACCGTGTC GAAGTTCAATGTCGGAGTTTCTGAG
SQSTM1 CGTCTGCCCAGACTACGACT GTGTCCGTGTTTCACCTTCC
ATG3 CCACGATTATGGTTGTTTGG GTGGCAGATGAGGGTGATTT
ATG7 ACCTTGGGTTGCAATGTAGC CTTACCACCCCCTAGGCAAT
Rabbit
RUNX2 CTTCACAAATCCTCCCCAAG ATGCGCCCTAAATCACTGAG
OSX ATGGCGTCCTCTCTGCTTG GCTTCTCGTGCCTGCTTT
COLA1 Life Technologies (Paisley, UK): Reference number. OC 03 396116_A 1
OPG GTGCACTTGGTTTGCTGCTA CCTGAAGAATGCCTCCTCAC
RANKL AAAATGAAGATTTGCAAGACG TTTCTCGGCTCTCAGGTGTT
DAP12 CTGGTGTTGACCCTGCTCAT TGACTCGGTCTCAGTGATGC
CD16B GACCTCCACATTCCAGAAGC GAGAACGGAGGACGAGATGA
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expression were calculated using the 2-ΔCT method [19]. For protein expression ana-
lysis, PBMCs were seeded at 100,000 cells/cm2 and cultured for 14 days in α–MEM sup-
plemented with 10 % FBS, 100 IU/ml penicillin and 100 μg/ml streptomycin. After
14 days the cell monolayer was washed with ice-cold 1xPBS, and lysates were prepared by
adding lysis buffer containing protease and phosphatase inhibitors. Lysates were scraped
into a 1.5 ml microcentrifuge tube, and centrifuged for 15 min at 4 °C. Supernatants were
transferred to fresh microcentrifuge tubes and stored at −80 °C. The protein concentra-
tion was determined by the Pierce BCA Protein Assay (VWR, Leuven, Belgium). Equal
amounts of protein were loaded onto each lane of a 4–12 % Bis-Tris gel and subjected to
electrophoresis under reducing conditions. After blotting, polyvinylidene difluoride mem-
branes were blocked for one hour (5 % milk powder in 0.1 % PBS/Tween) and incubated
with the appropriate antibody overnight at 4 °C. Antibodies were purchased from Abcam,
Cambridge, UK (p62, LC3, Beta-Actin), or Cell Signaling Technology, Danvers, MA
(Atg5, H3K9, H3K27, H3). Protein levels were normalized to the median control levels.
Binding of the secondary antibody was visualized by enhanced chemiluminescence (ECL).
Analysis of global histone methylation status and interaction with autophagy signaling in
patient osteoclasts
Global methylation of histone H3 lysine 9 (H3K9me3) and lysine 27 (H3K27me3),
which both result in global repression of gene expression, was compared to total his-
tone and beta-actin in freshly isolated PBMCs and mature osteoclasts from healthy
controls and critically ill patients by Western blotting. In an attempt to elucidate the
role of autophagy and histone modifications in aberrant osteoclast formation in critic-
ally ill patients, the SABioscience RT2 Profiler™ PCR Arrays (Qiagen Benelux) for Au-
tophagy and Epigenetic Chromatin Modification Enzymes were utilized. These qPCR
arrays profile the expression of 84 key genes representative of autophagy and epigenetic
Owen et al. Intensive Care Medicine Experimental  (2015) 3:19 Page 5 of 16chromatin modifications. PBMCs were cultured for 14 days with 10 % FBS, and total
RNA was isolated using the RNeasy kit (Qiagen Benelux) as previously described. The
single strand cDNA from 1 μg total RNA was synthesised using RT2 first strand kit
(SABioscience). Real-Time PCR was performed according to the User Manual of RT2
Profiler PCR array system (SABioscience) using SYBR Green PCR Master Mix in a
StepOnePlus PCR system (Applied Biosystems). Data analysis was carried out using the
online SABioscience Array data analysis software, and genes were identified as up- or
down-regulated with a 2–fold or higher change in expression. Using Ingenuity Pathway
Analysis (IPA) software, networks for >2–fold down-regulated epigenetic genes and up-
regulated autophagy genes were created.
2. In vivo rabbit model of bone loss during critical illness
Animals
The study protocol was approved by the KU Leuven Ethical Review Board for Animal
Research (P108/2009). All animals were treated according to the Principles of Labora-
tory Animal Care (U.S. National Society for Medical Research) and the Guide for the
Care and Use of Laboratory Animals (National Institutes of Health). In our animal
model, critical illness was induced by burn injury, which has previously shown to reveal
the dynamic endocrine and metabolic changes characteristic of critical illness, including
hyperglycemia, and endogenous insulin deficiency. This model has previously been
characterized and validated as a robust in vivo model of critical illness [20]. At day 0,
adult, 3– to 4–month-old male New Zealand White rabbits were anesthetized and
catheters were inserted in the right jugular vein and right carotid artery, allowing intra-
venous infusion of fluids and repetitive blood sampling, respectively. Thereafter, a para-
vertebral block was performed using lidocaine (Xylocaine, AstraZeneca, Brussels, Belgium),
and a full thickness third-degree burn injury was inflicted on the flanks (n = 12) (15–20 %
body surface area; painless by itself as cutaneous nerves for sensation of pain are
destroyed). Immediately after burn injury, rapamycin-treated animals (n = 6) received an
intramuscular injection of 0.06 mg/kg rapamycin (Rapamune; Pfizer Limited, Sandwich,
UK) followed by a 0.05–mg/kg injection after 24 and 48 hrs. During the first day, animals
received fluid resuscitation consisting of Hartmann enriched with 5 % glucose (Baxter,
Lessines, Belgium), which was replaced by parenteral nutrition (33.3 % Oliclinomel
N7 (Baxter), 33.3 % Hartmann, and 33.3 % Glucose 50 %) at day 1. Animals were tar-
geted to hyperglycemia throughout the 3–day study period, which was selected to en-
sure autophagy-related changes were observed. This group was compared with a
similarly treated group not receiving rapamycin (n = 6) and with healthy animals (n = 4).
All animals survived until day 3 and were anesthetised and sacrificed by cardiectomy. The
left and right tibiae were dissected, dipped in polyvinyl alcohol, and snap-frozen in liquid
nitrogen, and stored at −80 °C until further analysis.
Bone quantification and gene expression
Peripheral quantitative computed tomography (pQCT; Stratec XCT Research densi-
tometer, Norland Medical Systems, Fort Atkinson, WI, USA) was used to assess the
cortical area and strength-strain index. Using a voxel size of 0.070 mm, slices of
0.2 mm thickness were obtained. Three metaphyseal scans were taken 2.4 mm from
the proximal end of the tibia and an inner threshold was set to 30 % of the total cross-
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rabbits were decalcified in 10 % ethylenediaminetetraacetic acid (EDTA) at 4 °C in
order to enable sectioning of tissues [16]. After 6 weeks, the tibiae were processed to
paraffin and sections of 5 μm thickness were cut and stained for H&E, and the amount
of trabecular bone quantified by ImageJ® software (National Institutes of Health) [4].
Gene expression analysis was performed on the trabecular bone of the right tibia of
critically ill rabbits as previously described [3].
Statistical analysis
The data were processed using the Statistical software package StatView 5.0.1 (SAS In-
stitute Inc.). Student’s t test was used for the comparison of normally distributed data
(presented as mean ± SD), and the Mann–Whitney U test for data that were not nor-
mally distributed (presented as median and IQR, unless otherwise indicated). P values
less than or equal to 0.05 were considered statistically significant. Statistical significance
is indicated on all graphs as follows: *: p < 0.05, **: p < 0.01, ***: p < 0.001.Results
Autophagy is deficient in PBMCs and osteoclasts from critically ill patients
Freshly isolated PBMCs and PBMCs grown in culture for 14 days were analysed for the
expression of markers of autophagy in critically ill patients compared to matched
healthy controls. Freshly isolated PBMCs (Day 0 of culture) from critically ill patients
displayed lower levels of Atg5 protein than those from healthy controls. Levels of
LC3–II were unchanged, and an accumulation of p62 protein was observed, suggest-
ing autophagy was already supressed in these non-cultured precursor cells. Addition-
ally, in PBMCs which had been differentiated in culture for 14 days, protein levels of
both Atg5 and LC3–II were decreased when compared to cultured cells from healthy
controls. In addition, p62 protein levels were increased, suggesting an accumulation
in p62 (Fig. 1a). Unsurprisingly, markers of mature osteoclast differentiation (TRAF6,
CD16B, NFATc1) were significantly increased in mature cultured osteoclasts from
critically ill patients compared to healthy controls (1.6–fold, 17.5–fold, and 1.9–fold,
respectively; p < 0.05; Fig. 1b, I, II, and III). Expression of autophagy genes SQSTM1
which is the gene encoding p62, and Atg3 were not significantly different between cell
populations, whereas Atg7 was significantly lower, by 3.5–fold, in patient cells com-
pared to healthy controls (p < 0.01; Fig. 1b, IV, V, and VI).
Addition of the autophagy inducer rapamycin to critically ill patient PBMCs in vitro leads
to decreased osteoclast formation
To further examine the role of autophagy in bone loss in an in vitro model relevant for
the human condition of critical illness, PBMCs were isolated, and pooled from an age-,
sex-, and BMI-matched set of critically ill patients and healthy controls, and analysed
for osteoclast formation in the presence of the autophagy inducer rapamycin. After
14 days of culture, the formation of mature, multi-nuclear (≥3 nuclei, TRAP positive
osteoclasts was increased by 65 % in PBMC cultures from critically ill patients than
those from healthy controls (Fig. 2a and b; p < 0.001). The addition of rapamycin reduced
osteoclast formation by 36 % in patient cultures (Fig. 2a and b; p < 0.05).
Fig. 1 Deficient autophagy in critically ill patient PBMCs. (a) Undifferentiated PBMCs from critically ill patients
displayed decreased levels of Atg5 and increased levels of p62 protein, suggesting autophagy was already
deficient in these cells. In PBMCs grown for 14 days in culture, protein levels of both Atg5 and LC3–II were
decreased, in combination with an accumulation in p62. (b) At the level of gene expression, markers of mature
osteoclast differentiation (TRAF6, CD16B, NFATc1) were significantly increased in osteoclasts from critically ill
patients compared to healthy controls (1.6-fold, 17.5–fold, and 1.9–fold, respectively; p < 0.05). Expression of
autophagy markers SQSTM1, the gene encoding p62, and Atg3 were not significantly different between cell
populations, however, Atg7 was significantly decreased by 3.5–fold in patient cells compared to healthy
controls (p < 0.01) (n = 3; *p < 0.05; **p < 0.01)
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critically ill patient osteoclasts
In PBMCs and mature osteoclasts from critically ill patients, global histone methylation
at histone H3 methylated Lys9 (H3K9) and histone H3 methylated Lys27 (H3K27) was
lower than in those from healthy controls, whilst levels of unmethylated histone H3
Fig. 2 Induction of autophagy in vitro leads to decreased osteoclast formation in critically ill patient PBMCs.
(a) The formation of mature, multi-nuclear (≥3 nuclei, tartrate-resistant acid phosphatase (TRAP) positive)
osteoclasts was quantified visually using ImageJ software. (b) After 14 days in culture, osteoclast formation
increased by 65 % in PBMC cultures from critically ill patients than those from healthy controls. The addition of
rapamycin did not alter osteoclast formation in healthy control cultures, however, in patient cultures, osteoclast
formation was reduced by 36 % (n = 6; *p < 0.05; ***p < 0.001)
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key genes, 10 genes were up-regulated by 2–fold or more and 12 which were down-
regulated in patient osteoclasts compared to healthy controls (Table 3). The epigenetic
modification array analyzing osteoclast RNA revealed up-regulation of only one gene
(PRMT8, 13.4–fold), whilst 21 genes were down-regulated by 2–fold or more (Table 4).
Using the Ingenuity Pathway Analysis site, a number of down-regulated chromatin
modification enzymes (namely DOT1L, RPS6KA5, MLL, KAT2A, SUV39H1, HDAC1,
and HDAC7) could be linked to an up-regulation of genes that are related to inhibition
of autophagy (HTT and BC2L1) (Fig. 3b).
Addition of the autophagy inducer rapamycin restores bone loss in critically ill rabbits
in vivo
In order to examine the direct effect of an autophagy inducer in critically ill rabbits,
trabecular, and cortical area were analysed in sick rabbits treated with rapamycin or sa-
line. After 3 days, the number of trabeculae was not significantly lower in critically ill
rabbits compared to controls (15.3 % (p = 0.20); Fig. 4a). The trabecular area, however,
was reduced by 44.1 % (p ≤ 0.05), (Fig. 4b). The cortical area and bone mineral content
(BMC) from sick rabbits were significantly lower than in controls (12.1 % (p ≤0.05) and
(12.2 % (p ≤ 0.05) respectively (Fig. 4d and e)), as was the Strength-Strain Index (SSI)
(16.1 % (p ≤0.05), Fig. 4f. Rapamycin treatment of critically ill rabbits resulted in a sig-
nificantly higher number of trabeculae (31.1 %), increased cortical area (6.9 %), BMC
(6.9 %), and SSI (13 %) compared to untreated critically ill rabbits (Fig. 4a–f ).
To investigate the effect of rapamycin on osteoblast differentiation the gene expres-
sion of RUNX2, OSX, and COL1A1 were measured in the trabecular bone of critically
ill rabbits treated with rapamycin or saline and in healthy control rabbits. The expres-
sion of these 3 markers was significantly lower in the critically ill rabbits than in
healthy controls (RUNX2: 54 % (p ≤ 0.01), OSX: 64.3 % (p ≤ 0.01) and COL1A1: 57.9 %
Fig. 3 Aberrant epigenetic modifications are linked to alterations in the autophagy pathway in critically ill
patient osteoclasts. (a) Global histone methylation at histone H3 methylated Lys9 (H3K9) and histone H3
methylated Lys27 (H3K27) was decreased in freshly isolated PBMCs and mature osteoclasts from critically ill
patients compared to healthy controls, whilst levels of unmethylated histone H3 were unchanged. (b)
Using the Ingenuity Pathway Analysis site, a number of down-regulated chromatin modification enzymes
(namely DOT1L, RPS6KA5, MLL, KAT2A, SUV39H1, HDAC1, and HDAC7) could be linked to up-regulated
genes related to inhibition of autophagy (HTT and BC2L1), suggesting that histone hypomethylation may
be associated with deficient autophagy in critically ill patient osteoclasts (red network hubs = autophagy-
related genes; blue network hubs = chromatin modification-related genes)
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Table 3 Change in expression of autophagy-related genes in critically ill patient osteoclasts
Gene Name Fold Change
HTT 4.02
ATG9A 3.79
GAA 3.67
LAMP1 3.08
EIF4G1 2.77
DAPK1 2.64
RGS19 2.43
ATG16L2 2.15
TGFB1 2.08
BCL2L1 2.01
TMEM74 −6.56
IRGM −5.52
IGF1 −5.44
TNF −4.73
ATG10 −3.35
IFNG −3.32
PTEN −3.31
CXCR4 −3.16
FAS −2.84
PRKAA1 −2.81
MAP1LC3B −2.73
GABARAPL2 −2.06
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and COLA1 (p = 0.04) expression compared to critically ill rabbits treated with saline.
Osteoclast differentiation in trabecular bone was assessed through the gene expres-
sion of markers of 2 alternative signalling pathways attributing to osteoclastogenesis,
RANKL/RANK/OPG, and CD16, as we have previously shown that CD16 signalling is
essential for osteoclastogenesis during critical illness [3]. No change in the RANKL/
OPG ratio was observed critically ill rabbits as previously reported (Fig. 5d), however a
trend for increased CD16b and DAP12 expression was observed (89.5 % and 45.1 %,
respectively), which was reversed with rapamycin (Fig. 5e and f ).Discussion
In the current study we have investigated the role of autophagy in critical illness-
induced bone loss, and the potential role of epigenetic changes. The cellular control of
autophagy in human critical illness was studied in vitro, where PBMC osteoclast pre-
cursors in the blood of critically ill patients displayed markers of supressed autophagy,
which was maintained upon differentiation into mature osteoclasts. Furthermore, treat-
ment with the autophagy inducer rapamycin resulted in an inhibition of pathological
osteoclast formation from patient PBMCs. Interestingly, global histone methylation was
reduced in patient PBMCs and osteoclasts, and this was associated with an increase in
the expression of autophagy-inhibiting genes such as BCL2L1. It is known that female
Table 4 Change in expression of epigenetically-related genes in critically ill patient osteoclasts
Gene Name Fold Change
PRMT8 +13.45
PRMT6 −11.22
HDAC7 −5.25
KDM5C −4.00
HDAC11 −3.86
HDAC10 −3.54
DNMT3A −3.33
KDM6B −3.33
MLL −2.98
DNMT3B −2.78
USP21 −2.58
RPS6KA5 −2.55
SETD6 −2.53
SUV39H1 −2.42
PRMT1 −2.35
WHSC1 −2.25
DOT1L −2.22
AURKB −2.18
DZIP3 −2.17
HDAC1 −2.12
KDM4A −2.03
KAT2A −2.00
Owen et al. Intensive Care Medicine Experimental  (2015) 3:19 Page 11 of 16survivors of critical illness display increased fracture risk up to 8 years following ICU
discharge [2], and we have previously shown that trabecular bone is lost in a rabbit
model of critical illness [3, 4]. In the current study, we have expanded these findings by
showing that the administration of an autophagy inducer ameliorates critical illness-
induced bone loss.
We have previously shown that autophagy is insufficiently activated in liver, kidney,
and skeletal muscle of critically ill rabbits [3, 8]. Additionally, in critically ill human pa-
tients, autophagy appears insufficiently activated to adequately clear cell damage in
skeletal muscle. By tolerating an important macronutrient deficit for one week in the
ICU, however, this insufficient activation was ameliorated [21, 22]. Pharmacological ac-
tivation of autophagy may be a strategy to improve outcome, as also shown in our ani-
mal model of critical illness [8]. The importance of adequately functioning autophagy
for normal osteoclast differentiation is apparent in Paget’s Disease of Bone, where mu-
tations in the ubiquitin binding protein p62/SQSTM1 results in aberrant osteoclasto-
genesis [5]. In the current study, in addition to an increase in markers of osteoclast
differentiation, we observe a reduction in Atg5 and Atg7 expression, coupled with re-
duced LC3–II expression. This suggests a suppressed activation of autophagy, which is
supported by reduced SQSTM1 gene expression. Interestingly, it has previously been
shown that Atg5 and Atg7 are required for the active function of osteoclasts as bone-
resorbing cells, but not for osteoclast formation [6]. Therefore, we cannot exclude the
possibility that the decrease in Atg enzymes observed in the current study combined
Fig. 4 Induction of autophagy restores bone loss in critically ill rabbits. (a) After 3 days, there was a trend
(p = 0.2) for a reduction in number of trabeculae (b) and a significant reduction in trabecular area (c) in
critically ill rabbits compared to controls. Similarly, the cortical area (d) cortical bone mineral content (BMC) (e)
and strength strain index (SSI) (f) was significantly reduced. Critically ill rabbits treated with rapamycin displayed
a significantly higher number of trabeculae, cortical area, and SSI compared to untreated sick rabbits (p < 0.05;
n = 6 per group)
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servation of an accumulation in p62 protein in patient osteoclasts reinforces the hy-
pothesis that the autophagy process is deficient during critical illness.
Induction of autophagy with the mTOR inhibitor rapamycin significantly reduced
aberrant osteoclast formation in patient PBMC cultures, but had no effect on healthy
control PBMCs, supporting the hypothesis that deficient autophagy plays a key role in
the extreme osteoclast formation observed in critical illness.
Fig. 5 Induction of autophagy restores the expression of osteoblast differentiation markers in trabecular
bone of critically ill rabbits. The expression of RUNX2 (a), OSX (b), and COLA1 (c) was significantly decreased in
the critically ill rabbits as compared to healthy controls (p < 0.05; n = 6 per group). (d) No change in the RANKL/
OPG ratio was observed critically ill rabbits, however a trend for increased CD16b (e) and DAP12 (f) expression
was observed (n = 6 per group)
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in cell survival. In particular, methyltransferases such as G9a have been shown to co-
ordinate the transcriptional activation of key regulators of autophagosome formation
by remodeling the chromatin landscape [23]. In the current study, global hypomethyla-
tion was observed at H3K9 and H3K27 in patient PBMCs and osteoclasts in vitro. The
expression of key developmental genes is often regulated by H3K9 and H3K27 hyper-
or hypomethylation, and in mature osteoclasts, H3K27 at the promoter region of
NFATc1 gene is markedly hypomethylated [11]. In order to investigate whether altered
global histone methylation could be linked with autophagy signaling in critically ill pa-
tient osteoclasts, PCR arrays for autophagy, and chromatin modification enzymes were
carried out. Interestingly, the most up-regulated gene in the autophagy array was HTT,
encoding for the huntingtin protein. Previous studies have shown that deficient autoph-
agy results in a marked increase in HTT protein expression, due to inefficient deg-
radation [24], and blocking autophagy in models of Huntingdon’s disease in vitro (in
adrenal medulla cells or striatal cells) raised levels of exogenously expressed HTT,
reduced cell viability, and increased the number of cells bearing mutant HTT aggre-
gates [14]. Importantly, when down-regulated genes from the chromatin modifica-
tion PCR array were combined with up-regulated genes from the autophagy array, a
network was created with HTT appearing as a key network hub gene, in addition to
BCL2L1, which inhibits autophagy by binding to the BH3 domain of beclin 1 [25].
These genes were associated with a number of down-regulated methyltransferases
such as SUV39H1, MLL, and DOT1L, in addition to histone deacetylases HDAC1,
HDAC7, and KAT2A. However, whether hypomethylation is the direct cause of the
up-regulation of both HTT and BCL2L1 cannot be elucidated from this data, and
additional studies are required to confirm whether there is a direct link between
Owen et al. Intensive Care Medicine Experimental  (2015) 3:19 Page 14 of 16deficient autophagy and epigenetic alterations in aberrant osteoclast formation
during critical illness.
We have previously shown that rabbits made critically ill for one week displayed bone
loss and displayed signs of insufficiently activated autophagy in other organs and tissues
[3, 21]. In the current study, administration of the mTOR inhibitor rapamycin was pro-
tective against signs of trabecular and cortical bone loss after only 3 days. In addition,
reductions in the expression of osteoblast differentiation markers were also partially
restored with rapamycin, whilst trends towards an increase in immune-related osteo-
clastogenic markers CD16b and DAP12 in sick rabbits were reduced with rapamycin.
Interestingly, it has recently been shown that autophagy is induced in osteoblasts dur-
ing mineralization, and that autophagy deficiency reduces mineralization capacity [26].
Furthermore, a recent study has reported a similar finding in mice with giant cell
tumor of bone (GCT), a benign type of tumor with hyperactive multinucleated giant
osteoclasts which can cause local osteolytic lesions therefore increasing morbidity. The
treatment of GCT mice with rapamycin resulted in reduced osteoclast formation by
switching the expression of C/EBPβ isoforms [7]. Similarly, arthritic mice treated with
rapamycin or everolimus, an alternative mTOR inhibitor, displayed an improvement in
arthritic symptoms and reduced osteoclast formation suggesting rapamycin could be a
promising therapy for metabolic bone disease [27]. However, one major caveat with the
use of rapamycin is it's immunosuppressant properties, which make it unsuitable for
the treatment of critically ill patients. In addition, we cannot exclude that the reduced
osteoclast formation in vitro and improved bone phenotype observed in critically ill
rabbits treated with rapamycin is due to the immunosuppressive effects of rapamycin
rather than its autophagy-inducing properties. In addition, we cannot exclude the pos-
sibility that the bone-sparing effects observed with rapamycin are not due to direct ef-
fects on osteoclasts and osteoblasts in the trabecular bone, but are secondary to
alterations in the immune system, inflammation, or angiogenesis. Consequently, further
work is required to identify therapies that induce autophagy but do not cause immuno-
suppressant side effects in critically ill patients.Conclusion
The present study has confirmed that PBMCs from critically ill patients are predis-
posed to form an increased number of mature osteoclasts compared to PBMCs from
healthy controls. This increase in osteoclast formation is associated with deficient au-
tophagy, which may be mediated by global histone modifications. Treatment with the
autophagy inducer rapamycin reversed these findings in vitro and in an in vivo rabbit
model of critical illness, reduced the amount of bone loss. These findings may help to
develop novel therapeutic targets to prevent critical illness-induced bone loss.Competing interests
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